Longevity research measures biomarkers (telomere length, mitochondrial function, inflammatory markers), not life expectancy. No compound in the longevity peptides family has been shown to extend lifespan or long-term health in humans, and that fact should frame everything you read about them.
Of everything in the catalog, longevity peptides are where the gap between enthusiasm and evidence is widest. This article tries to describe that gap precisely rather than take sides.
The nine hallmarks of aging as a framework
In 2013 a group of researchers proposed a framework that has become a reference point for the field: the hallmarks of aging, the cellular and molecular processes that characterize how organisms grow old. The expanded 2023 version lists twelve.
The ones cited most often in connection with peptides:
| Hallmark | What it describes |
|---|---|
| Telomere shortening | Chromosome ends get shorter with every division |
| Mitochondrial dysfunction | Cellular energy production deteriorates |
| Altered intercellular communication | Includes chronic low-grade inflammation |
| Deregulated nutrient sensing | Pathways such as mTOR, AMPK, and sirtuins |
| Cellular senescence | Cells that stop dividing but do not die |
The framework is useful because it organizes the research. What it does not do, and this is where the trouble starts, is guarantee that acting on a hallmark changes aging. A hallmark is an observed feature of the process, not necessarily a lever that controls it.
What a longevity study actually measures
Almost no longevity study measures longevity. It sounds like a paradox. It is literal.
Measuring life expectancy in humans would require decades of follow-up and enormous samples. For an investigational molecule that is logistically out of reach. What gets measured instead are markers associated with aging:
- Telomere length.
- Inflammatory markers such as IL-6 or CRP.
- Measures of mitochondrial function.
- The so-called epigenetic clocks, based on DNA methylation patterns.
- Functional measures: grip strength, gait speed, cognitive function.
Each one is statistically associated with aging or with mortality in population studies. For none of them has it been shown that changing the marker changes the outcome.
Biomarker versus outcome: the central gap
This is the idea that makes everything else useful, and it is a direct application of the distinction between a marker and a clinical outcome.
That a marker is associated with an outcome does not mean that causing it produces the outcome. Medicine offers plenty of examples: interventions that improved a marker convincingly and made the clinical result worse.
Applied to this field: lengthening telomeres is not the same as living longer. Telomere shortening is associated with aging; it does not follow that lengthening telomeres artificially is beneficial. In fact, the relationship between telomerase activity and uncontrolled cell proliferation is one reason the scientific community treats this target with caution rather than enthusiasm.
The catalog compounds and the hallmark each one touches
| Compound | Hallmark addressed | Level of evidence |
|---|---|---|
| Epitalon | Telomere shortening, circadian rhythm | Mostly Russian literature, with limited independent replication |
| NAD+ | Nutrient sensing, mitochondrial function | Human trials with precursors; effects on outcomes, not demonstrated |
| MOTS-c | Mitochondrial function, AMPK signaling | Preclinical; no controlled human trials |
Each of these longevity peptides has its own article: epitalon, NAD+, and MOTS-c.
Why animal longevity models almost never replicate
The longevity field has a particularly poor replication record, for reasons worth knowing:
Strain effects. A compound that extends lifespan in one mouse strain may fail to do so in another. The genetic variability between strains is enough to flip the result.
Site effects. The same experiment run in different laboratories produces different results, because of differences in diet, microbiota, and housing conditions. Multi-site replication programs exist for exactly this reason.
Caloric restriction confounds the picture. Many interventions reduce food intake as a side effect, and caloric restriction on its own extends lifespan in several models. Separating the two effects requires study designs that are not always used.
Publication bias. Negative results get published less often, which inflates the apparent efficacy of the entire field.
Six questions for any anti-aging claim
A practical filter, usable on any product or headline:
- What was measured, a marker or an outcome? If it was a marker, the claim is about the marker.
- In which species? Most of the data come from rodents or cell culture.
- Has it been replicated independently? In this field that is the decisive question.
- Was there a control group and randomization?
- Was the effect of caloric restriction controlled for?
- Was the study registered before it began? That lets you check that the reported outcome is the one it set out to measure.
Very few claims in this field pass all six.
What the evidence does not settle
Close to everything asked of it:
- No compound in this family has been shown to extend lifespan or healthspan in humans.
- There are no hard-outcome trials under way for any of them.
- The causal link between the markers and aging is not established in most cases.
- Very long-term safety, the horizon over which a longevity compound would make sense, is by definition unknown.
The honest frame for this whole cluster is promising research, not proven. That is less than the market promises, and it is not nothing: there is real biology and there are legitimate questions behind it. What there are not are answers.
Frequently asked questions
Does any peptide extend lifespan?
None has demonstrated it in humans. What exists are studies on markers associated with aging, which is a far more modest claim.
Why measure telomeres if it is not clear they matter?
Because telomere shortening is robustly associated with cellular aging and it can be measured. The association is solid; what is not established is that changing telomere length changes the outcome.
So mouse studies are worthless?
They are worth something as hypothesis generators. In longevity specifically, the replication rate across strains and laboratories is low, which forces a more cautious reading than in other areas.
Is all of this smoke and mirrors, then?
No. There is real biology and there are plausible mechanisms. What is missing is any demonstration of an effect on what matters. Confusing "not demonstrated" with "false" is as wrong as confusing it with "demonstrated."
References
- López-Otín C, et al. The Hallmarks of Aging. Cell, 2013;153(6):1194–1217. DOI: 10.1016/j.cell.2013.05.039
- López-Otín C, et al. Hallmarks of aging: An expanding universe. Cell, 2023;186(2):243–278. DOI: 10.1016/j.cell.2022.11.001
- Nadon NL, et al. NIA Interventions Testing Program: Investigating Putative Aging Intervention Agents in a Genetically Heterogeneous Mouse Model. EMBO Journal, 2017. DOI: 10.15252/embj.201797621
- Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics, 2018;19:371–384. DOI: 10.1038/s41576-018-0004-3
- Prasad V, et al. The strength of association between surrogate end points and survival in oncology. JAMA Internal Medicine, 2015;175(8):1389–1398. DOI: 10.1001/jamainternmed.2015.2829
Written by the Bionic Editorial Team. Last reviewed: August 2026.
How we work: our editorial policy and source hierarchy.
This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.